about
Innovative surgical approaches for hepatocellular carcinomaMicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?Targeting Angiogenesis in Biliary Tract Cancers: An Open OptionImmunotherapeutic approaches for hepatocellular carcinomaEverolimus restrains the paracrine pro-osteoclast activity of breast cancer cells.The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy.The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy.Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance.Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer.Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinomaAngiogenesis in pancreatic ductal adenocarcinoma: A controversial issueMetronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study.Novel lenalidomide-based combinations for treatment of multiple myeloma.Bone metastases in hepatocellular carcinoma: an emerging issue.Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma.Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?Multimodal treatment of resectable pancreatic ductal adenocarcinoma.Immunotherapy for colorectal cancer: where are we heading?In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells.Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib.Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors.Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review.Angiogenesis in adenosquamous cancer of pancreas.Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough.Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma.Mast cells and angiogenesis in pancreatic ductal adenocarcinoma.Paraneoplastic focal segmental glomerulosclerosis in sarcomatoid renal cell cancer.Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro.Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Nefrologia (SIN).Bone metastases in biliary cancers: A multicenter retrospective surveyMulticenter Prospective Study of Angiogenesis Polymorphism Validation in HCC Patients Treated with Sorafenib. An INNOVATE Study ProtocolSystemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors: A Retrospective Multicenter AnalysisCAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic CancerStrategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review.Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targetsBone metastasis as primary presentation of pancreatic ductal adenocarcinoma: A case report and literature reviewPredictive and Prognostic Factors in HCC Patients Treated with Sorafenib
P50
Q26750640-C0A22949-4EB3-4B16-818C-B84F3E4B5E85Q26799779-17D663DF-3F6E-43A6-8A68-27C475E8A8CAQ30398807-FBA1DA04-99FD-4241-9F3B-21272E4736E3Q33779723-B2B55F36-E44D-4024-BF3E-1E7CCF667AABQ35807838-F306BCFE-6A07-4C12-A1DD-786D513C0D8FQ36214152-DB21FA93-3838-4375-9A51-9240B15D8283Q36785251-3ED67051-2390-4FD4-AE9C-D9B7FB7D387DQ37013255-A757864B-FD17-41BF-B58A-BF9DCD3232EAQ37096730-71AFEF1A-3131-4C31-AB98-B3BFE9ACD29EQ37142991-3AB62E50-8F11-43A0-8E1C-88B37F901710Q37629083-C8897674-B7C7-4A70-A362-F7E58A680ECBQ37637994-1DEA160B-7A7E-4D60-9E64-1BAC7C9CECD7Q38027256-3D08B876-8FB0-40C0-82FB-154011E1F402Q38172848-BB1BD26F-4E25-4A92-9598-F3FCE2487A49Q38554626-3C47D777-7E35-4175-82A1-871BF07DE4E6Q38665086-229F0DD7-63F5-41CF-A623-252294E40484Q38672368-E62BCAF0-B2C2-45BB-95AC-92F449B440C4Q38835601-D49EFA2A-5371-402E-BFAE-9B7A22C9EA53Q39161424-AD7846B2-DCBB-4263-8F2F-3026CBC5D604Q39218636-F752CB86-01BA-4898-BF6F-690F727E2DE6Q39379196-467BCDDD-303C-483F-A7A1-B7B5BB0365EDQ40380730-DBA273A1-BA9D-4723-BD46-59E1060B4725Q40975849-D7C6C75D-26A8-4B3E-B8BC-61076844CD0AQ42371684-321A9D58-37EF-486F-A57D-073580A94904Q47119323-9D95C6B2-CE9B-40A4-817B-A92BC8C1BDEFQ47686470-41FD6806-0FBD-4B80-B54E-FAC0C8DDE3CAQ47915753-9FCB9B47-0083-4A8D-A2D5-A928153D386CQ50512896-991F2BD0-3008-4D06-A812-0B7596E8D584Q52689003-05CCA897-77C8-46E3-BB0D-C690F1614B28Q53073457-8B693D9F-AC1A-4FA7-B39C-BD5FE664DF87Q54373221-16F4D827-0065-4FE0-8FFB-45629BA0E51AQ55019941-FAE2041A-0D6B-406B-8609-1B187F89A1FEQ56387056-8F8CEF67-6D85-4B5E-B564-8A09C6CBADFBQ56927812-7D682420-88BE-4B90-A1BE-98099772ECCAQ57178818-4B2E7050-BBF2-4C57-9214-CD890242FA9BQ64119749-505ADE97-EDA9-40B9-B5C4-EAF16A715261Q64964791-55C3B72D-AC4B-4844-8891-DEC4586AED88Q88117846-939A7EF1-D455-49FD-B9E3-97698AA6482EQ90783761-746EFF36-E509-421C-879C-A16C28225ADAQ90877592-FCB02D8A-C32B-4785-8A9E-52E53CDE30DA
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Oronzo Brunetti
@ast
Oronzo Brunetti
@en
Oronzo Brunetti
@es
Oronzo Brunetti
@nl
Oronzo Brunetti
@sl
type
label
Oronzo Brunetti
@ast
Oronzo Brunetti
@en
Oronzo Brunetti
@es
Oronzo Brunetti
@nl
Oronzo Brunetti
@sl
prefLabel
Oronzo Brunetti
@ast
Oronzo Brunetti
@en
Oronzo Brunetti
@es
Oronzo Brunetti
@nl
Oronzo Brunetti
@sl
P1053
J-5898-2017
P106
P1153
53363079400
P21
P31
P3829
P496
0000-0002-7014-6828
P569
2000-01-01T00:00:00Z